Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Transkaryotic Therapies

  • News

Executive Summary

Transkaryotic Therapies: Initial public offering would consist of 2.5 mil. shares at $13-$15 per share, Cambridge, Mass.-based Transkaryotic announces Aug. 27. Morgan Stanley, UBS Securities and Pacific Growth Equities will underwrite the IPO. Transkaryotic has "two proprietary technology platforms," the company says: gene activation and a non-viral, ex vivo gene therapy system. Clinical trials of gene-activated erythropoietin are scheduled to begin in the first half of 1997 under a collaboration with Hoechst Marion Roussel...

Table

View full table

Tags:
Latest Headlines

US FDA Inspectors, Product Centers Working Closer Together Ahead Of ORA Reorg

Not-For-Profit Models Needed For Commercially Unviable Rare Disease Drugs

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

Swissmedic Gets New Grant For Regulatory Strengthening In LMICs

See All
UsernamePublicRestriction

Register

PS028798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By